Universal Beteiligungs und Servicegesellschaft mbH Sells 6,545 Shares of Natera, Inc. $NTRA

Universal Beteiligungs und Servicegesellschaft mbH decreased its stake in Natera, Inc. (NASDAQ:NTRA) by 5.1% during the 2nd quarter, HoldingsChannel reports. The fund owned 120,636 shares of the medical research company’s stock after selling 6,545 shares during the period. Universal Beteiligungs und Servicegesellschaft mbH’s holdings in Natera were worth $20,380,000 as of its most recent filing with the Securities and Exchange Commission.

Several other large investors have also recently bought and sold shares of the stock. Price T Rowe Associates Inc. MD boosted its holdings in Natera by 56.3% in the 1st quarter. Price T Rowe Associates Inc. MD now owns 10,537,743 shares of the medical research company’s stock valued at $1,490,144,000 after purchasing an additional 3,795,315 shares during the period. Nuveen LLC acquired a new position in shares of Natera during the first quarter valued at about $113,375,000. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC lifted its stake in shares of Natera by 140.4% in the first quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 1,253,790 shares of the medical research company’s stock valued at $177,298,000 after buying an additional 732,156 shares during the period. JPMorgan Chase & Co. raised its holdings in Natera by 9.9% in the 1st quarter. JPMorgan Chase & Co. now owns 7,361,963 shares of the medical research company’s stock valued at $1,041,055,000 after acquiring an additional 660,538 shares in the last quarter. Finally, Ninety One UK Ltd lifted its position in shares of Natera by 149.1% in the 2nd quarter. Ninety One UK Ltd now owns 562,985 shares of the medical research company’s stock worth $95,111,000 after acquiring an additional 336,985 shares during the period. 99.90% of the stock is currently owned by institutional investors and hedge funds.

Insiders Place Their Bets

In other news, CEO Steven Leonard Chapman sold 160,703 shares of the firm’s stock in a transaction on Monday, November 3rd. The stock was sold at an average price of $199.96, for a total value of $32,134,171.88. Following the completion of the sale, the chief executive officer directly owned 144,816 shares in the company, valued at approximately $28,957,407.36. This trade represents a 52.60% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available through this link. Also, CFO Michael Burkes Brophy sold 1,867 shares of Natera stock in a transaction dated Wednesday, October 29th. The shares were sold at an average price of $190.64, for a total value of $355,924.88. Following the completion of the transaction, the chief financial officer directly owned 64,126 shares of the company’s stock, valued at $12,224,980.64. This represents a 2.83% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Over the last quarter, insiders sold 223,336 shares of company stock valued at $42,990,633. Company insiders own 5.63% of the company’s stock.

Natera Stock Up 3.7%

Shares of NTRA stock opened at $213.65 on Wednesday. The company has a market capitalization of $29.49 billion, a P/E ratio of -93.30 and a beta of 1.75. Natera, Inc. has a 12-month low of $125.38 and a 12-month high of $215.81. The firm has a 50-day moving average price of $183.03 and a 200 day moving average price of $166.54.

Natera (NASDAQ:NTRA) last posted its quarterly earnings data on Friday, November 7th. The medical research company reported ($0.64) earnings per share for the quarter, missing the consensus estimate of ($0.39) by ($0.25). The firm had revenue of $592.18 million for the quarter, compared to analyst estimates of $514.55 million. Natera had a negative return on equity of 25.07% and a negative net margin of 14.61%.The business’s quarterly revenue was up 34.7% on a year-over-year basis. During the same period in the previous year, the business posted ($0.26) EPS. As a group, research analysts expect that Natera, Inc. will post -1.49 earnings per share for the current year.

Wall Street Analyst Weigh In

Several equities research analysts have issued reports on the stock. Morgan Stanley boosted their price target on shares of Natera from $195.00 to $220.00 and gave the company an “overweight” rating in a report on Tuesday, November 11th. Evercore ISI lifted their target price on shares of Natera from $190.00 to $250.00 and gave the company an “outperform” rating in a research report on Friday, November 7th. Barclays upped their target price on shares of Natera from $210.00 to $230.00 and gave the company an “overweight” rating in a research note on Friday, November 7th. Canaccord Genuity Group raised their price target on shares of Natera from $200.00 to $250.00 and gave the stock a “buy” rating in a research note on Friday, November 7th. Finally, Royal Bank Of Canada set a $268.00 price objective on Natera and gave the company an “outperform” rating in a report on Tuesday, September 2nd. Fifteen equities research analysts have rated the stock with a Buy rating, three have given a Hold rating and two have assigned a Sell rating to the stock. According to MarketBeat, the stock currently has an average rating of “Moderate Buy” and an average price target of $220.29.

Natera Company Profile

Natera, Inc, a diagnostics company, develops and commercializes molecular testing services worldwide. Its products include Panorama, a non-invasive prenatal test that screens for chromosomal abnormalities of a fetus, as well as in twin pregnancies; Horizon carrier screening test for individuals and couples determine if they are carriers of genetic variations that cause certain genetic conditions; Vistara single-gene NIPT screens for 25 single-gene disorders that cause severe skeletal, cardiac, and neurological conditions; Spectrum, preimplantation genetic tests for couples undergoing IVF; Anora that analyzes miscarriage tissue from women; Empower, a hereditary cancer screening test; and non-invasive prenatal paternity product, which allows a couple to establish paternity without waiting for the child to be born.